Immunoglobulin G1 [351-alanine,386-alanine,387-alanine] anti-(human epidermal growth factor receptor HER2) (human-Mus musculus monoclonal IMM2902 ?1-chain), disulfide with 1-125-signal regulatory protein ? [80-alanine] (human isoform 4 variant) fusion protein with peptide linker ((GGGGS)3) fusion protein with human-Mus musculus monoclonal IMM2902 ?-chain, dimer
Advanced Gastric Carcinoma
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.monoclonal_antibodyPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 89/ 100
Competitive context
48 Active assets in the Advanced Gastric Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan City of Hope Medical Center | Phase 1/2 | CCC |
gsk1120212 National Cancer Institute (NCI) | Phase 2 | CCC |
Dabrafenib National Cancer Institute (NCI) | Phase 2 | CCC |
Nivolumab National Cancer Institute (NCI) | Phase 2 | CCC |
Gdc-0449 National Cancer Institute (NCI) | Phase 2 | CCC |
View all 50 →
Same molecule, other indications
Immunoglobulin G1 [351-alanine,386-alanine,387-alanine] anti-(human epidermal growth factor receptor HER2) (human-Mus musculus monoclonal IMM2902 ?1-chain), disulfide with 1-125-signal regulatory protein ? [80-alanine] (human isoform 4 variant) fusion protein with peptide linker ((GGGGS)3) fusion protein with human-Mus musculus monoclonal IMM2902 ?-chain, dimer is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →